Emulate, a Boston, MA-based developer of Organs-on-Chips technology platform, expanded its Series B financing raising an additional $17m.
This brought the total amount raised in the round to $45m.
Backers includes new private individuals, institutional and non-institutional funds, which joined initial investors Hansjörg Wyss, NanoDimension, Cedars-Sinai Medical Center, OS Fund, Atel Ventures, ALS Finding a Cure (a program of the Leandro P. Rizzuto Foundation), and Laboratory Corporation of America® Holdings (LabCorp®).
The company intends to use the funds to accelerate its R&D efforts, expedite the launch of its products and expand strategic relationships with industry and academic partners.
Led by James Coon, Chief Executive Officer, Emulate has created a new living Human Emulation SystemTM, which provides a real-time window into the inner workings of human biology and disease. Its lab-ready system, which includes Organ-Chips, instrumentation and software apps, is designed to provide an R&D platform that predicts human response to diseases, medicines, chemicals and foods with greater precision and detail than cell culture or animal testing experimental methods, offering researchers a new technology designed to predict human response with greater precision and detail than today’s cell culture or animal-based experimental testing.
Each of Emulate’s proprietary Organ-Chips – such as the lung, liver, brain or kidney – contains tiny hollow channels lined with tens of thousands of living human cells and tissues, and is approximately the size of an AA battery. An Organ-Chip is a living, micro-engineered environment that recreates the natural physiology and mechanical forces that cells experience within the human body.